Stem cell shot aims to tame rheumatoid arthritis

NCT ID NCT04971980

Ongoing Disease control Sponsor: Beijing Baylx Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a single intravenous infusion of stem cells from donated umbilical cords (BC-U001) in 9 adults with moderate-to-severe rheumatoid arthritis who haven't responded well to standard treatments. The main goal is to check safety and find the right dose, while also looking for signs of reduced joint inflammation and disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord stem cells (BC-U001)
What this could lead to: If successful, this could point toward a new way to control rheumatoid arthritis with a single infusion, reducing inflammation and joint damage.
What could go wrong: This is a very early, small trial (9 people) focused on safety, not proof of effectiveness. The treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Peking Union Medical College Hospital (Dongdan campus)

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.